Novel antidepressant shines in phase 2 trial, but FDA has issues with its NDAAugust 12, 2021DepressionAlzheimer's & CognitionMental Health
COVID-19 tied to acceleration of Alzheimer’s disease pathologyAugust 6, 2021Alzheimer's & CognitionCOVID-19 UpdatesNeurology
‘Alarming’ data on early cognitive decline in transgender adultsAugust 6, 2021Alzheimer's & CognitionNeurologyTransgender Health
‘Staggering’ increase in global dementia cases predicted by 2050July 29, 2021Alzheimer's & CognitionNeurologyGeriatrics
First guidance on appropriate use of controversial Alzheimer’s drugJuly 28, 2021Alzheimer's & CognitionNeurology
More on GRADE: Cognitive deficits linked to CV risk factors in T2DJuly 27, 2021DiabetesCardiologyAlzheimer's & Cognition
Zero benefit of aducanumab for Alzheimer’s disease, expert panel rulesJuly 16, 2021Alzheimer's & CognitionGeriatricsNeurology
Contentious Alzheimer’s drug likely to get national coverage plan, CMS saysJuly 14, 2021Alzheimer's & CognitionBusiness of MedicineNeurologyGeriatrics
FDA updates label for controversial Alzheimer’s drug aducanumab (Aduhelm)July 8, 2021Alzheimer's & CognitionNeurology
Chronic stress and genetics can raise the risk of Alzheimer’s diseaseJuly 7, 2021Alzheimer's & CognitionGeriatricsNeurology
Hearing loss tied to decline in physical functioningJuly 2, 2021GeriatricsMental HealthNeurologyMusculoskeletal DisordersPreventive CareAlzheimer's & CognitionDepression
